What is Trialjectory?
Trialjectory operates as a patient-first digital health platform that leverages artificial intelligence to bridge the gap between cancer patients and advanced clinical treatment options. By empowering individuals to take ownership of their medical journey, the company utilizes real-world data analytics to provide actionable insights. This patient-centric model not only improves individual outcomes but also aggregates community-wide data to inform broader clinical decision-making. As a leader in the health-tech space, Trialjectory is effectively disrupting traditional oncology care pathways by prioritizing transparency, accessibility, and data-driven empowerment for patients worldwide.
How much funding has Trialjectory raised?
Trialjectory has raised a total of $22.7M across 2 funding rounds:
Angel/Seed
$2.7M
Series A
$20M
Angel/Seed (2019): $2.7M with participation from Contour Venture Partners
Series A (2022): $20M led by Tia Ventures, Contour Venture Partners, JAL Ventures, Rho Ventures, and Insight Partners
Key Investors in Trialjectory
Tia Ventures
A seed-stage venture capital fund based in New York City that invests in exceptional B2B software companies led by high-execution teams.
Contour Venture Partners
A seed stage venture capital firm founded in 2005 that focuses on investing in innovative software solutions within the enterprise SaaS and financial services sectors.
JAL Ventures
A venture capital firm providing expansion capital to early-revenue Israeli technology companies with a focus on high-value enterprise solutions.
What's next for Trialjectory?
With the infusion of this recent capital, Trialjectory is well-positioned to accelerate its enterprise-level growth and expand its technological footprint. The strategic roadmap likely involves scaling its AI capabilities to handle larger datasets, thereby increasing the precision of its treatment matching algorithms. Furthermore, the company is expected to deepen its partnerships with healthcare providers and research institutions, solidifying its role as a standard-bearer for patient-led clinical trial matching. By focusing on sustainable scalability and operational excellence, Trialjectory aims to transform the oncology ecosystem, ensuring that data-driven care becomes the industry benchmark for patient outcomes.
See full Trialjectory company page
